[Urothelial cancers from Endoxan]

A case of carcinoma of the bladder in a patient treated for 20 years with Endoxan is reported. The role of this drug in the aetiology of an urothelial carcinoma was appeared to be demonstrated by the 35 published cases in the literature and should lead to a limitation of its prescription and to regulate urological surveillance of patients receiving the agent.